Summit Theraperutics shares are trading higher after HC Wainwright maintained a Buy rating on the stock and raised its price target from $16 to $30.
Portfolio Pulse from Benzinga Newsdesk
Summit Therapeutics shares rose after HC Wainwright maintained a Buy rating and increased the price target from $16 to $30.
September 09, 2024 | 11:29 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Summit Therapeutics shares are trading higher following HC Wainwright's decision to maintain a Buy rating and raise the price target from $16 to $30.
The increase in price target from $16 to $30 by HC Wainwright, along with the maintained Buy rating, is a strong positive signal for investors, likely leading to increased buying interest and a rise in the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100